D Jeffrey Keyser bought LTRN once, on May 12, 2026

Donald “Jeff” Keyser is an American biopharmaceutical executive and corporate director who serves as Chairman of the Board and director of Lantern Pharma Inc. (NASDAQ: LTRN), where he has been a director since January 2018 and Chairman since November 2019.( As a corporate insider at Lantern Pharma, he has reported equity-based compensation, including recent option grants under the company’s Amended and Restated 2018 Stock Incentive Plan.(

Keyser is President and CEO (and previously described as president and chief operating officer) of Renibus Therapeutics, a clinical-stage biopharmaceutical company developing therapies for the diagnosis, treatment, and prevention of kidney and related cardio‑renal‑metabolic diseases.( He co‑founded ZS Pharma, serving as director and chief operating officer from 2008 until its acquisition by AstraZeneca in 2015 for $2.7 billion, and earlier invented the Mucinex product line for Adams Respiratory Therapeutics, where he also led R&D and regulatory strategy before the company’s $2.3 billion acquisition by Reckitt Benckiser.( His earlier career includes senior regulatory and compliance roles at Encysive Pharmaceuticals, Medeva Americas, Marion Merrell Dow, and Abbott Laboratories.( Keyser holds a pharmacy degree (RPh) and Juris Doctor from Creighton University, an MPA from the University of Missouri–Kansas City, and a PhD in Economics from The University of Texas at Dallas.(

Written by Perplexity from public sources.